Anti‐EGFR scFv tetramer (tetrabody) with a stable monodisperse structure, strong anticancer effect, and a long in vivo half‐life

The development of single‐chain variable fragments (scFvs) as therapeutic agents has the potential to reduce the high cost of antibody production, but the development process often impairs scFv functions such as binding affinity and pharmacokinetics. Multimerization is one strategy for recovering or...

Descripción completa

Detalles Bibliográficos
Autores principales: Asano, Ryutaro, Koyama, Noriaki, Hagiwara, Yasuyo, Masakari, Yosuke, Orimo, Ryota, Arai, Kyoko, Ogata, Hiromi, Furumoto, Shozo, Umetsu, Mitsuo, Kumagai, Izumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4887975/
https://www.ncbi.nlm.nih.gov/pubmed/27419062
http://dx.doi.org/10.1002/2211-5463.12073

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4887975/
https://www.ncbi.nlm.nih.gov/pubmed/27419062
http://dx.doi.org/10.1002/2211-5463.12073

Ejemplares similares